We found that a reduced PLAGL1 level was clearly negatively associated with a worse OS of TCGA-PAAD cohort patients, while the association between PLAGL1 and disease-free survival (DFS) was not significant (Fig. 4a, b). Here, PLAGL1 is linked to pancreatic adenocarcinoma.